Pharmaceuticals company Shukra Pharmaceuticals announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Revenue from operations: For Q4FY26, revenue stood at Rs 630.29 lakh, representing a YoY decrease of 52.50% from Rs 1,326.98 lakh in Q4FY25 and a QoQ decrease of 83.89% compared to Rs 3,913.48 lakh in Q3FY26. For FY26, revenue reached Rs 5,670.61 lakh, representing a growth of 74.01% YoY from Rs 3,258.73 lakh in FY25. Total Income: For Q4FY26, total income was Rs 725.01 lakh, a YoY decrease of 50.80% from Rs 1,473.51 lakh and a QoQ decrease of 81.85% from Rs 3,995.01 lakh in Q3FY26. For FY26, total income reached Rs 6,129.10 lakh, up 66.58% YoY from Rs 3,679.39 lakh in FY25. Net Profit/Loss: The company reported a Net Loss of Rs 172.67 lakh in Q4FY26, compared to a Net Profit of Rs 538.64 lakh in Q4FY25 and a Net Profit of Rs 2,036.46 lakh in Q3FY26. For FY26, Net Profit stood at Rs 2,204.79 lakh, marking an increase of 130.26% YoY from Rs 957.51 lakh in FY25. Total Comprehensive Income: For FY26, the annual total comprehensive income was Rs 2,196.08 lakh compared to Rs 958.59 lakh in FY25. Earnings per share (Face Value Rs 1): Basic and Diluted EPS for FY26 stood at Rs 0.50 compared to Rs 0.22 in FY25. Consolidated Financial Highlights: Total Revenue from operations: For Q4FY26, revenue was Rs 632.41 lakh, reflecting a YoY decrease of 52.34% from Rs 1,326.98 lakh in Q4FY25 and a QoQ decrease of 83.84% from Rs 3,913.48 lakh in Q3FY26. For FY26, revenue reached Rs 5,672.74 lakh, a YoY growth of 85.46% from Rs 3,258.73 lakh in FY25. Total Income: For Q4FY26, total income stood at Rs 727.13 lakh, a YoY decrease of 50.65% from Rs 1,473.51 lakh and a QoQ decrease of 81.80% from Rs 3,995.01 lakh in Q3FY26. For FY26, total income was Rs 6,131.22 lakh, up 66.64% YoY from Rs 3,679.39 lakh in FY25. Net Profit/Loss: The Group reported a Net Loss of Rs 171.62 lakh in Q4FY26, compared to a Net Profit of Rs 538.64 lakh in Q4FY25 and a Net Profit of Rs 2,036.46 lakh in Q3FY26. For FY26, Net Profit was Rs 2,205.84 lakh, reflecting a YoY growth of 130.37% from Rs 957.51 lakh in FY25. Total Comprehensive Income: For FY26, the annual consolidated total comprehensive income reached Rs 2,197.13 lakh compared to Rs 958.59 lakh in FY25. Business Highlights Dividend: The Board recommended a Final Dividend of Rs 0.01 (1%) per equity share of face value Re 1 each fully paid for the financial year FY26. Preferential Allotment: The Board approved the allotment of 17,35,000 fully paid-up equity shares of face value Re 1 each to Dakshesh Shah and Parshva Texchem India Private Limited (Promoters), following the conversion of warrants at an issue price of Rs 34 per share. Equity Capital: Consequent to the allotment, the paid-up equity capital of the company increased to Rs 43,96,14,440 consisting of 43,96,14,440 equity shares of Re 1 each. Warrants Reconciliation: As of May 07, 2026, a total of 29,08,000 warrants remain outstanding for conversion out of the 46,43,000 warrants allotted on November 01, 2025. Segment-wise Performance (Consolidated FY26): Pharmaceutical Segment: Reported annual revenue of Rs 6,129.10 lakh and a segment profit of Rs 2,986.59 lakh before tax and interest. Medtech Segment: Reported annual revenue of Rs 0.00 and no separate segment profit for the year. The segment name "Shukra MedTech" became effective from October 1, 2025. Subsidiary Results: The consolidated results include the financial performance of four subsidiaries: Shukra Diabetes Technologies Private Limited, Shukra Health Tech Private Limited, Shukra Robotics Private Limited, and Shukra Woundcare Private Limited. Result PDF
Pharmaceuticals company Shukra Pharmaceuticals announced Q3FY26 results Revenue: Rs 3,913.48 lakh against Rs 1,058.43 lakh during Q3FY25, change 270%. PBT: Rs 2,683.15 lakh against Rs 409.48 lakh during Q3FY25, change 555%. PAT: Rs 2,036.46 lakh against Rs 316.44 lakh during Q3FY25, change 544%. EPS: Rs 0.47 for Q3FY26. Result PDF